We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says Most Accelerated Oncology Approvals Went on to Prove Clinical Benefit
FDA Says Most Accelerated Oncology Approvals Went on to Prove Clinical Benefit
Most oncology treatments that received the FDA’s accelerated approval pathway in the past 25 years have demonstrated a clinical benefit, according to a review by agency officials published in the journal JAMA Oncology.